Evolus Inc
NASDAQ:EOLS

Watchlist Manager
Evolus Inc Logo
Evolus Inc
NASDAQ:EOLS
Watchlist
Price: 12.6 USD -3.37% Market Closed
Market Cap: 797.8m USD
Have any thoughts about
Evolus Inc?
Write Note

Intrinsic Value

The intrinsic value of one EOLS stock under the Base Case scenario is 17.71 USD. Compared to the current market price of 12.6 USD, Evolus Inc is Undervalued by 29%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

EOLS Intrinsic Value
17.71 USD
Undervaluation 29%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Evolus Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for EOLS cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about EOLS?
Bearish
Neutral
Bullish

Fundamental Analysis

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Evolus Inc

Provide an overview of the primary business activities
of Evolus Inc.

What unique competitive advantages
does Evolus Inc hold over its rivals?

What risks and challenges
does Evolus Inc face in the near future?

Has there been any significant insider trading activity
in Evolus Inc recently?

Summarize the latest earnings call
of Evolus Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Evolus Inc.

Provide P/S
for Evolus Inc.

Provide P/E
for Evolus Inc.

Provide P/OCF
for Evolus Inc.

Provide P/FCFE
for Evolus Inc.

Provide P/B
for Evolus Inc.

Provide EV/S
for Evolus Inc.

Provide EV/GP
for Evolus Inc.

Provide EV/EBITDA
for Evolus Inc.

Provide EV/EBIT
for Evolus Inc.

Provide EV/OCF
for Evolus Inc.

Provide EV/FCFF
for Evolus Inc.

Provide EV/IC
for Evolus Inc.

Show me price targets
for Evolus Inc made by professional analysts.

What are the Revenue projections
for Evolus Inc?

How accurate were the past Revenue estimates
for Evolus Inc?

What are the Net Income projections
for Evolus Inc?

How accurate were the past Net Income estimates
for Evolus Inc?

What are the EPS projections
for Evolus Inc?

How accurate were the past EPS estimates
for Evolus Inc?

What are the EBIT projections
for Evolus Inc?

How accurate were the past EBIT estimates
for Evolus Inc?

Compare the revenue forecasts
for Evolus Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Evolus Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Evolus Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Evolus Inc compared to its peers.

Compare the P/E ratios
of Evolus Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Evolus Inc with its peers.

Analyze the financial leverage
of Evolus Inc compared to its main competitors.

Show all profitability ratios
for Evolus Inc.

Provide ROE
for Evolus Inc.

Provide ROA
for Evolus Inc.

Provide ROIC
for Evolus Inc.

Provide ROCE
for Evolus Inc.

Provide Gross Margin
for Evolus Inc.

Provide Operating Margin
for Evolus Inc.

Provide Net Margin
for Evolus Inc.

Provide FCF Margin
for Evolus Inc.

Show all solvency ratios
for Evolus Inc.

Provide D/E Ratio
for Evolus Inc.

Provide D/A Ratio
for Evolus Inc.

Provide Interest Coverage Ratio
for Evolus Inc.

Provide Altman Z-Score Ratio
for Evolus Inc.

Provide Quick Ratio
for Evolus Inc.

Provide Current Ratio
for Evolus Inc.

Provide Cash Ratio
for Evolus Inc.

What is the historical Revenue growth
over the last 5 years for Evolus Inc?

What is the historical Net Income growth
over the last 5 years for Evolus Inc?

What is the current Free Cash Flow
of Evolus Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Evolus Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Evolus Inc

Current Assets 150.4m
Cash & Short-Term Investments 85m
Receivables 44.6m
Other Current Assets 20.7m
Non-Current Assets 79.2m
PP&E 10.6m
Intangibles 67.8m
Other Non-Current Assets 858k
Current Liabilities 60.8m
Accounts Payable 13.8m
Accrued Liabilities 23.3m
Other Current Liabilities 23.7m
Non-Current Liabilities 162.9m
Long-Term Debt 121.2m
Other Non-Current Liabilities 41.7m
Efficiency

Earnings Waterfall
Evolus Inc

Revenue
248.3m USD
Cost of Revenue
-74.6m USD
Gross Profit
173.7m USD
Operating Expenses
-205.3m USD
Operating Income
-31.6m USD
Other Expenses
-23.9m USD
Net Income
-55.5m USD

Free Cash Flow Analysis
Evolus Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

EOLS Profitability Score
Profitability Due Diligence

Evolus Inc's profitability score is 53/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Year Average ROE
Positive Gross Profit
Exceptional 3-Years Revenue Growth
Exceptional ROE
53/100
Profitability
Score

Evolus Inc's profitability score is 53/100. The higher the profitability score, the more profitable the company is.

EOLS Solvency Score
Solvency Due Diligence

Evolus Inc's solvency score is 25/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Positive Net Debt
Long-Term Solvency
High D/E
25/100
Solvency
Score

Evolus Inc's solvency score is 25/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

EOLS Price Targets Summary
Evolus Inc

Wall Street analysts forecast EOLS stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for EOLS is 23.9 USD with a low forecast of 20.2 USD and a high forecast of 28.35 USD.

Lowest
Price Target
20.2 USD
60% Upside
Average
Price Target
23.9 USD
90% Upside
Highest
Price Target
28.35 USD
125% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for EOLS?

Click here to dive deeper.

Dividends

Evolus Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for EOLS is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

EOLS Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

EOLS News

Other Videos

Profile

Evolus Inc Logo
Evolus Inc

Country

United States of America

Industry

Pharmaceuticals

Market Cap

797m USD

Dividend Yield

0%

Description

Evolus, Inc. is a medical aesthetics company, which engages in the provision of medical aesthetic treatments and procedures. The company is headquartered in Newport Beach, California and currently employs 167 full-time employees. The company went IPO on 2018-02-08. The Company’s first commercial product is Jeuveau, which is an approximately 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the self-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications that are not reimbursed by any third-party payor, such as Medicaid, Medicare or commercial insurance. The company offers customers and consumers a compelling value proposition with Jeuveau. BOTOX (onabotulinumtoxinA) is also an approximately 900 kDa botulinum toxin type A complex approved in the United States.

Contact

CALIFORNIA
Newport Beach
520 Newport Center Dr Ste 1200
+19492844555.0
www.evolus.com

IPO

2018-02-08

Employees

167

Officers

President, CEO & Director
Mr. David Moatazedi
Chief Financial Officer
Ms. Sandra Beaver
Chief Medical Officer and Head of Research & Development
Dr. Rui Avelar C.CFP, Dip.SportMed, M.D.
Head of Global Investor Relations & Corporate Communications
Mr. Nareg Sagherian
General Counsel
Mr. Jeffrey J. Plumer
Vice President of Sales
Mr. Kurt Knab
Show More
Chief Marketing Officer
Ms. Tomoko Yamagishi-Dressler
Senior Vice President of Human Resources
Ms. Jessica Novak
Show Less

See Also

Discover More
What is the Intrinsic Value of one EOLS stock?

The intrinsic value of one EOLS stock under the Base Case scenario is 17.71 USD.

Is EOLS stock undervalued or overvalued?

Compared to the current market price of 12.6 USD, Evolus Inc is Undervalued by 29%.

Back to Top